Viatris Inc.'s pipeline of new biosimilars and other drugs faced undisclosed, stiff competition during a period when the company’s leadership touted its product launches as a way to offset “erosion” in its existing business lines, an investor alleges.
Viatris saw disappointing revenue and a resulting 24% stock-price decline, shareholder Jason Taylor says. His suit was entered in the docket Tuesday in the US District Court for the Western District of Pennsylvania.
Taylor is suing on behalf of a proposed class of those who acquired Viatris common stock between March 1, 2021, and February 25, 2022—a time when the company and ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.